Federal contractor · COLUMBIA, MD

A&G PHARMACEUTICAL, INC.

A&G PHARMACEUTICAL, INC. received -$27.7K in federal contract obligations in FY2026, on 3 awards (−211% vs FY2025). Since FY2017: $527.1K. Its largest customer was National Institutes of Health (-$27.7K).

Obligations · FY2026
-$27.7K
New awards
3
Sole-source
—
Single offer
—
UEI
SN6SWFABJXL1
Other than small business
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. -17.2KFY2017
  2. -8.5KFY2018
  3. 175KFY2019
  4. 43.9KFY2020
  5. 132.7KFY2021
  6. 66.4KFY2022
  7. 43.6KFY2023
  8. 93.9KFY2024
  9. 24.9KFY2025
  10. -27.7KFY2026

Top buying agencies

Obligations in FY2026.

  1. National Institutes of Health-$27.7K0.0%
    3 awards

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Largest awards

  1. POLYCLONAL RAT ANTIBODY AND MONOCLONAL RAT ANTIBODIES AGAINST GLYCOL-CHITOSAN NANOPARTICLES$83.4K
    National Institutes of Health· Montgomery County, MD· Research & development· Jun 30, 2022 – May 5, 2026· 75N95022F00001
  2. PRECISION ANTIBODY (AMBIS #2229539) LAB TESTING, FUSION, CLONING$15.5K
    National Institutes of Health· Howard County, MD· Health & medical· Aug 27, 2024 – Apr 22, 2026· 75N93024P01059
  3. ANTIBODY DEVELOPMENT SERVICES FOR MALARIAL ORGANELLES$0
    National Institutes of Health· Howard County, MD· Health & medical· Aug 16, 2021 – Aug 26, 2026· 75N93021P01162

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

A&G PHARMACEUTICAL, INC. received $0 in federal assistance in FY2026, on 1 actions (0 new awards).

Assistance · FY2026
$0
New awards
0
Actions
1
Since FY2021
$939.6K

Assistance by fiscal year

  1. 141.7KFY2021
  2. 897.8KFY2022
  3. 0FY2023
  4. -99.8KFY2024
  5. 0FY2025
  6. 0FY2026

Largest awards

  1. PHARMACOLOGY & HUMAN PHASE 1 SAFETY & DOSE ESCALATION STUDIES USING ANTI-GP88 IN AGGRESSIVE BREAST CANCER$2M
    93.395 · Cancer Treatment Research· National Institutes of Health· Project grant· Mar 19, 2021 – Jul 17, 2026· R44CA224718

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2021–FY2026.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

This section could not be loaded right now. Reload the page to try again.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026.